- Home
- EAD vs ALT Comparison
EAD vs ALT Comparison
Compare EAD & ALT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | EAD | ALT |
|---|---|---|
| Founded | 2003 | 1997 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance/Investors Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 407.1M | 415.3M |
| IPO Year | N/A | 2005 |
Fundamental Metrics
Financial Performance| Metric | EAD | ALT |
|---|---|---|
| Price | $6.82 | $4.33 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $16.00 |
| AVG Volume (30 Days) | 148.6K | ★ 3.1M |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | ★ 8.91% | N/A |
| EPS Growth | N/A | ★ 19.28 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $20,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $5.89 | $2.91 |
| 52 Week High | $7.18 | $7.73 |
Technical Indicators
Market Signals| Indicator | EAD | ALT |
|---|---|---|
| Relative Strength Index (RSI) | 46.76 | 41.40 |
| Support Level | $6.82 | $4.27 |
| Resistance Level | $6.83 | $4.53 |
| Average True Range (ATR) | 0.04 | 0.21 |
| MACD | -0.01 | -0.05 |
| Stochastic Oscillator | 30.96 | 11.59 |
Price Performance
Historical ComparisonAbout EAD Allspring Income Opportunities Fund
Allspring Income Opportunities Fund is a diversified closed-end management investment company. Its products and services are mutual funds, closed-end funds, managed accounts services, and variable trust funds. The fund's objective is a high level of current income and capital appreciation. Its portfolio of investments is Commercial services, healthcare services, Food, Pharmaceuticals, Energy, Oil & gas, Pipelines, Diversified financial services, and Others.
About ALT Altimmune Inc.
Altimmune Inc is a clinical-stage biopharmaceutical company focused on developing treatments for obesity, metabolic diseases, and liver diseases. Its product candidate, pemvidutide (formerly known as ALT-801), is a novel, investigational, peptide-based GLP-1/glucagon dual receptor agonist. Pemvidutide is currently in clinical development for obesity and metabolic-associated steatohepatitis (MASH). The company also plans to pursue additional indications for pemvidutide that leverage the differentiated clinical profile of pemvidutide.